Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. (OSIRIS)
Non-small-cell Lung Carcinoma
About this trial
This is an interventional diagnostic trial for Non-small-cell Lung Carcinoma focused on measuring Osimertinib, EGFR positive NSCLC, Resistance
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed metastatic NSCLC, characterized by a sensitizing EGFR mutation.
2. Progressive disease, as assessed by the treating physician during osimertinib monotherapy.
3. Eligible for subsequent treatment. 4. Willing to undergo a histological biopsy and withdrawal of a blood sample for ctDNA analysis.
5. Technically possible to take a histological biopsy.
Exclusion Criteria:
- 1. Osimertinib discontinuation before blood draw and / or histological tumor biopsy.
2. Initiation of a new line of anticancer therapy before blood draw and / or histological tumor biopsy.
Sites / Locations
- The Netherlands Cancer Institute-Antoni van LeeuwenhoekRecruiting
- Vrije Universiteit Medisch Centrum
- Universitair Medisch Centrum Groningen
- Academisch Ziekenhuis Maastricht
- Radboud Universitair Medisch Centrum
- Erasmus MC, Universitair Medisch Centrum Rotterdam
Arms of the Study
Arm 1
Other
Biopsy and blood
A histological core biopsy of a tumor lesion and a blood sample for ctDNA analysis will be collected